Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03466216 trial: what clinicians have said so far
Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET
- NCT03466216 ↗
- Terminated
- Orano Med LLC
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03466216 (AlphaMedix) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03466216 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A Phase 1, Non-Randomized, Open-Label, Dose Escalation, Single-Center Study to Determine the Safety, Bio-distribution, and Preliminary Effectiveness of AlphaMedix™ in Adult Subjects With SSRT(+) NETs.
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Neuroendocrine Tumor
- Interventions
- AlphaMedix
- Arms
- AlphaMedix · Experimental
- Enrollment
- 33
- Primary outcomes
- To determine dose-limiting toxicity (DLT)
- Incidence of treatment-emergent AEs and SAEs as assessed by CTCAE v. 4
- Sponsor
- Orano Med LLC
- Start
- Feb 5, 2018
- Primary completion
- Apr 6, 2023
- Results posted
- No
- Registry record
- NCT03466216 · updated Jun 10, 2025